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INTRODUCTION:  
Oral controlled release drug delivery have recently been of 
increasing interest in pharmaceutical field to achieve 
improved therapeutic advantages, such as ease of dosing 
administration, patient compliance and flexibility in 
formulation (1,2). Drugs with short half-lives and drugs that 
easily absorbed from gastrointestinal tract (GIT) are 
eliminated quickly from the systemic circulation. For these 
types of drugs the development of oral sustained-
controlled release formulations is an attempt to release the 
drug slowly into the gastrointestinal tract (GIT) and 
maintain an effective drug concentration in the systemic 
circulation for a long time (3,2). But oral sustained drug 
delivery formulations show some limitations connected 
with the gastric emptying time; variable and too rapid 
gastrointestinal transit could result in incomplete drug 
release from the device into the absorption window leading 
to diminished efficacy of the administered dose (4,2). 
Floating drug delivery system is an approach to prolong 
gastric residence time, thereby targeting site-specific drug 
release in the upper gastrointestinal tract (GIT) for local or 
systemic effects (4). In the present investigation, 
Salbutamol sulfate was selected as a model for the 
development of gartroretentive drug delivery system 
(GRFDDS). Salbutamol sulphate act as an b2 adrenergic 
receptor agonist widely used for the treatment of bronchial 
asthma, chronic bronchitis and emphysema (5). The drug 
undergoes extensive first-pass metabolism and thus 
requires frequent administrations by oral route (6). 
Salbutamol sulphate has a site-specific absorption in 
stomach and upper part of small intestine (7). Reported oral 
bioavailability of salbutamol sulphate is ~ 40 %; due to 
extensive metabolism via intestinal sulphonation, first pass 
metabolism in liver & also degradation in colon (8). The 
metabolism is due to extensive sulphonation in gut as 
compared to liver. The half life of Salbutamol sulphate is 
about 4.5 hrs (9). A gastroretentive drug delivery system 
may be advantageous over conventional oral dosage forms 
and inhalers due to its ability to maintain prolonged 
therapeutic concentrations in the systemic circulation (10).  
MATERIALS AND METHODS 
Materials:  
The drug Salbutamol sulphate was supplied as a gift 
sample by Ultra Lab Baddi (Himachal Pradesh). All other 
reagents and chemicals were of analytical grade. 
Preparation of floating tablet of Salbutamol sulphate: 
Floating Salbutamol sulphate tablet shall be prepared by 
using full 32 factorial design by varying the ratio of sodium 
bicarbonate and citric acid which was used as a gas 
generating agent. All tablets were prepared by wet 
granulation method. All the polymer and active ingredients 
were passed through sieve no. 80 separately. Required 
quantity of  Salbutamol sulphate,  polymers, gas 
generating, and diluents were mixed thoroughly in a glass 
motor pestle  and sufficient quantity of  binding agent  was 
added slowly to get dough mass. The mass was sieved 
through no.8 mesh and dried at 50˚C temperature for 1 hrs. 
The dried granules retained on 35 no. mesh were mixed 
with 10% fines, 2 % talc and 1% magnesium stearate and 
the tablet were punched with the help of automatic tablet 
punching machine with desired hardness, shape and size. 
The formulation parameters are listed below in table no.1. 
A Full 3
2
 factorial design were made by varying the 
ratio of gas generating agent: 
 
                       
ABSTRACT:  
The present investigation concerns with the development and evaluation of the floating matrix tablets of Salbutamol Sulphate. 
Tablets were prepared by wet granulation method.  Hydroxypropyl methylcellulose and ethyl cellulose was used as a release 
retardant material. Sodium bicarbonate and Citric acid was incorporated as a gas-generating agent. The effects of Sodium 
bicarbonate and citric acid on drug release profile, floating properties and matrix integrity of tablet were investigated. 
Addition of Citric acid in excess amount results in disintegration of the tablet so the floating tablets are prepared by full  32 
factorial designs by reducing the ratio of citric acid. Developed formulations were evaluated for their physical characteristics, 
drug content, floating lag time, floating duration, in vitro drug release profile etc. On the basis of various physical 
characteristics parameters it was found that all the formulations shows good result. On comparative kinetic modeling study 
such as (Zero order, Higuchi model and Korsmeyer-Peppas) it was found that all the formulations follow Higuchi model and 
correlation coefficient (R2) and Korsmeyer model values were nearer to unity. Among those formulations F8 and F9 showed 
R2 value of Higuchi model more near as compared to the other formulation.  
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Table 1: A Full 3
2
 Factorial Design of formulation F1 TO F9: 
 
EVALUATION PARAMETERS:  
A) Standard calibration curve of salbutamol sulphate 
in 0.1(N) HCL pH (1.2), and 0.2 (M) Phosphate buffer 
pH 6.8 was prepared: These standard graph are shown 
below in result and discussion chapter. 
B) Evaluation of Granules: The following evaluation 
parameters of granules were determined such as Angle of 
repose, Apparent bulk density, Tapped density, 
Compressibility index, Hausner’s ratio. The results are 
shown below in table no.2. 
C) Evaluation Of Salbutamol Sulphate Floating Tablet: 
These following evaluation parameters of salbutamol 
sulphate tablet was determined thourghly during my 
research work i.e General appearance, Thickness, 
Hardness, Weight variation, Friability, Drug Content, 
Swelling studies, Buoyancy lag time determination and 
Total floating time. The results of these various parameters 
are listed below in table no. 3. 
In-vitro dissolution study: 
In vitro drug release studies for the prepared floating 
tablets of salbutamol sulphate were conducted for a period 
of 10 hrs with an half of interval USP XXIV type-II 
(Paddle) dissolution apparatus at 37±0.5oC at 100 rpm 
using 900 ml of 0.1N HCl as dissolution medium for first 
two hrs and similarly for next seven hrs dissolution was 
conducted with 0.2M Phosphate buffer solution at a 
predetermined interval of time, 5 ml of sample was 
withdrawn from the dissolution medium and replaced with 
fresh medium to maintain the sink condition. After 
filtration and appropriate dilution, the samples were 
analyzed for salbutamol sulphate by UV 
spectrophotometer at 276 nm. Then the release kinetics of 
the drug salbutamol suphate was studied with the help of 
percentage cumulative drug release by using the models of 
release kinetics; such as Zero order release kinetics, First 
order release kinetics, Higuchi model and Korsmeyer-
Peppas model. 
RESULT AND DISCUSSION: 
A) Standard plot of salbutamol sulphate in 0.1 (N) 
HCL And 0.2 (M) Phosphate buffer solution: 
 
 
Graph no. 1: Standard plot of Salbutamol sulphate in 0.1 N HCL buffer solution: 
 
Graph no. 2: Standard plot of salbutamol sulphate in Phosphate buffer solution: 
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Formulation 
code 
Drug EC HPMC NaHCo3 Citric Acid Lactose Mg. 
Sterate 
(1%w/w) 
Talc 
(2%w/w) 
F1 12mg 40mg 30 mg 12%w/w=12mg 0%w/w=0mg 3mg 1mg 2mg 
F2 12mg 40mg 30 mg 10%w/w=10mg 0%w/w=0mg 5mg 1mg 2mg 
F3 12mg 40mg 30 mg 8%w/w=8mg 0%w/w=0mg 7mg 1mg 2mg 
F4 12mg 40mg 30 mg 12%w/w=12mg 0.5%w/w=0.5mg 2.5mg 1mg 2mg 
F5 12mg 40mg 30 mg 10%w/w=10mg 0.5%w/w=0.5mg 4.5mg 1mg 2mg 
F6 12mg 40mg 30 mg 8%w/w=8mg 0.5%w/w=0.5mg 6.5mg 1mg 2mg 
F7 12mg 40mg 30 mg 12%w/w=12mg 1%w/w=1mg 2mg 1mg 2mg 
F8 12mg 40mg 30 mg 10%w/w=10mg 1%w/w=1mg 4mg 1mg 2mg 
F9 12mg 40mg 30 mg 8%w/w=8mg 1%w/w=1mg 6mg 1mg 2mg 
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B) Evaluation of Granules: Evaluation parameters of granules are listed below in table no. 2: 
Table no. 2:  Shows various Evaluation parameters of granules: 
Formulation 
Code 
Bulk density (g/cc)           
± sd, n=3 
Tapped density 
(g/cc) ±sd, n=3 
Angle of repose 
(degree) ±sd, n=3 
Carr's Index (%) ± 
sd, n=3 
Hausner's 
Ratio ± sd, n=3 
F1 2.26± 0.20 6.47 ± 8.85 29.41±0.4761 8.77± 0.549 1.266 ± 0.169 
F2 0.182±0.0017 0.23± 0.02 27.28 ± 0.631 9.77 ± 0.207 1.373 ± 0.372 
F3 0.435 ±0.015 0.44 ± 0.016 26.133±0.507 9.12 ± 0.677 1.11 ± 0.008 
F4 0.28 ±0.0020 0.332±0.0020 30.126±0.843 14.74±0.282 1.16 ± 0.0163  
F5 152.6 ± 2.05 0.164±0.00163 23.22 ± 1.077 7.05 ± 0.658 1.08 ± 0.016 
F6 0.25 ± 0.016 0.282 ± 1.632 29.60 ± 0.656 10.75±0.449 1.12 ± 0.016 
F7 0.25 ± 0.81 0.266 ± 0.0016 26.31 ± 0.471 6.063±0.711 1.167 ± 0.002 
F8 0.002± 0.141 0.333 ± 1.632 29.06 ± 0.610 14.20±0.744 1.167 ± 0.002 
F9 0.200± 0.169 7.83 ± 10.7  27.7 ± 0.423 20.146±0.73 1.393 ± 0.188 
C) Evaluation of tablet:
 Evaluation parameters of tablet are listed below in table no. 3: 
Table 3: Evaluation of various parameters of all formulation of prepared tablet 
 
Table 4: shows In-vitro Dissolution Profile of Formulation F1 TO F9 in HCL buffer Ph 1.2 I.P for (1-2hr)and 
Phosphate buffer p.H 6.8 I.P for (10 hrs) 
Time Time 
% CAR 
F1 
% CAR 
F2 
% CAR 
F3 
% CAR 
F4 
% CAR 
F5 
% CAR 
F6 
% CAR 
F7 
% CAR 
F8 
% CAR 
F9 
0 0 0 0 0 0 0 0 0 0 0 
0.5 0.707 11.5 12.57 13.86 18.95 20.87 7.84 8.52 1.85 1.23 
1 1 18.3 18.08 21.8 21.84 25.56 11.26 11.09 5.25 4.78 
1.5 1.225 22.18 21.52 28.62 25.55 28.33 15.74 13.31 8.04 8.04 
2 1.414 30.18 22.17 31.27 27.42 33.83 21.92 15.37 14.22 13.3 
2.5 1.581 39.54 37.01 48.98 39.35 52.48 39.18 21.29 20.79 20.79 
3 1.732 48.06 41.57 53.14 43.12 56.06 41.12 23.78 26.01 25.08 
3.5 1.871 51.41 49.6 55.75 43.88 59.92 49.43 28.53 29 30.84 
4 2 52.72 55.99 57.61 49.8 63.23 52.87 34.05 33.46 34.2 
4.5 2.121 56.6 62.17 57.62 53.9 68.38 56.42 38.05 38.84 38.48 
5 2.236 59.19 62.57 57.99 57.99 69.5 57.21 40.35 42.76 38.87 
5.5 2.345 60.3 67.05 59.84 60.61 69.88 58.44 41.89 47.96 46.09 
6 2.449 60.68 71.17 67.99 64.87 71.15 60.29 45.3 51.5 51.5 
6.5 2.549 68.41 74.18 73.95 65.08 71.72 61.23 47.59 56.33 56.15 
7 2.646 72.87 79.04 74.85 65.45 75.74 61.54 48.55 62.83 60.25 
7.5 2.739 78.97 80.18 76.57 70.26 78.32 63.39 52.71 70.08 62.11 
8 2.828 79.55 81.68 77.32 73.43 82.36 67.09 54.63 75.11 63.23 
8.5 2.915 80.66 82.25 78.06 73.64 84.03 71.72 60.9 79.58 78.03 
9 3 81.4 82.44 81.58 87.88 84.59 74.98 65.29 83.49 80.53 
9.5 3.082 86.56 84.86 84.19 89.62 85.13 75.76 73.45 87.4 84.24 
10 3.162 89.71 88.41 87.9 91.29 90.07 76.7 79.56 90.38 88.7 
10.5 3.24 91.2 91.23 88.84 91.86 91.56 79.47 83.57 91.5 89.28 
11 3.317 91.4 92.18 92.18 92.6 91.94 80.06 87.56 94.28 89.65 
11.5 3.391 93.42 93.11 93.86 92.98 93.77 81.48 90.8 95.41 92.24 
12 3.464 94.72 94.98 95.35 93.9 95.06 81.96 93.28 96.53 95.4 
              
Formulation 
code 
Weight  
Variation 
   (mg) 
Diameter 
    (cm) 
Thickness 
    (cm) 
Hardness 
 (kg/cm2) 
Friability 
    (%) 
Drug (%) 
content 
1.2 pH   6.8pH     
Swelling 
index 
Lag 
Time 
 (sec) 
Total 
Floating 
Time(hr) 
   F1 100.4±4.4 8.00±0.017 3.05±0.064 2.63±0.124 0.8±0.008 97.83 97.08 56 105 12 
   F2 105.6±5.0 799±0.006 3.22±0.085 3.03±0.124 0.81±0.016 96.6 97.01 65 85 9 
   F3 99.36±2.9 7.96±0.001 3.17±0.110 3.23±0.205 0.85±0.028 97.37 96.60 68 45 10 
   F4 101.6±3.0 7.99±0.019 2.95±0.056 3.5±0.163 0.81±0.001 97.33 97.01 90 150 15 
   F5 97.33±3.0 7.99±0.016 3.13±0.067 3.16±0.205 0.81±0.016 98.43 97.45 68 80 12 
   F6 101.4±3.9 7.98±0.039 3.02±0.124 3.3±0.163 0.81±0.008 97.54 96.50 62 60 14 
   F7 96.8±3.2 7.97±0.017 3.02±0.124 3.2±0.163 0.80±0.005 95.06 96.01 77 180 14 
   F8 105.4±3.1 7.96±0.049 2.99±0.085 2.8±0.163 0.81±0.008 97.31 96.50 82 40 19 
   F9 100.8±2.8 7.99±0.021 3.00±0.061 2.3±0.163 0.81±0.008 97.31 98.08 91 80 22 
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Figure 3: in-vitro drug release profile of salbutamol sulphate F1 to F9 
 
                       
Figure no. 4: Shows Drug Release pattern of Formulation F1 to F9 followed Huguchi model 
 
Table 5: Comparision study of Cumulative % of drug release, R2 value, X120, t50 and t90:
 
FORMULATION 
CODE 
%CAR R2 VALUE 
ZERO     Higuchi 
X120 t50(hrs) t90(hrs) 
F1 
F2 
94.72 
94.98 
0.942      0.986 
0.918      0.974 
30.18 
22.17 
3.5 
4.0 
10.5 
10.5 
F3 95.35 0.915      0.983 31.27 4.5 11.0 
F4 93.9 0.960      0.978 27.42 2.5 10.0 
F5 95.06 0.876      0.974 33.83 4.0 10.0 
F6 81.96 0.895      0.964 21.92 7.5 12 
F7 93.28 0.915      0.987 15.37 6.0 11.5 
F8 96.53 0.936      0.989 14.22 6.0 10.0 
F9 95.4 0.935      0.989 13.3 6.0 11.5 
                         
 
Table 6: Shows Korsmeyer-Peppas release kinetics 
 
  RELEASE EXPONENT              DRUG TRANSPORT                    
MECHANISM 
RATE AS A FUNCTION  
         OF TIME 
0.5  
0.5<n<1.0  
1.0  
Higher than 1.0 
Fickian diffusion  
Anomalous transport                    
Case-II transport  
Super Case-II transport 
  t-0.5  
   t n-1  
  Zero-order release  
   tn-1 
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Table 7: Model Fitting analysis for formulation F1 to F9 
FORMULATION 
CODE 
KORSMEYER-PEPPAS 
N 
DIFFUSION MECHANISM 
 
F1 
F2 
F3 
F4 
F5 
F6 
F7 
F8 
F9 
0.776 
0.758 
0.730 
0.749 
0.783 
0.534 
0.596 
0.841 
0.752 
Non-Fickian Anamalous 
Non- Fickian Anamalous 
Non- Fickian Anamalous 
Non- Fickian Anamalous 
Non- Fickian Anamalous 
Non- Fickian Anamalous 
Non- Fickian Anamalous 
Non- Fickian Anamalous 
Non- Fickian Anamalous 
 
DISCUSSION: 
Apparent tablet density of all samples showed below 
(1.004g/cm3) than of gastric fluid. The density decreased 
due to this expansion and upward force of CO2 gas 
generation. This plays an important role in ensuring the 
floating capability of the dosage form. To provide good 
floating behavior in the stomach, the density of the tablets 
should be less than that of the gastric contents. The drug 
release data were fitted to models representing zero order 
(cumulative amount of drug released vs. time), Higuchi’s 
(cumulative percentage of drug released vs. square root of 
time), and Korsmeyer’s equation (log cumulative 
percentage of drug released vs. time) kinetics to know the 
release mechanisms. Among  all the formulations F8 and 
F9 showed R2 value of Higuchi model value nearer to unity 
as compared to the other formulations. The Korsmeyer-
Peppas (n) data suggest that all formulation show non- 
fickian transport. Among those formulations F8 
formulation were best fitted with korsmeyer model 
according to n- value. 
 
CONCLUSION: 
Gastro retentive floating tablets of Salbutamol sulphate 
were prepared using two hydrophilic polymer like ethyl 
cellulose and HPMC by full 32 factorial design by 
changing the ratio of gas generating agent. Nine 
formulations were prepared. All those formulation showed 
good acceptable Pharmacotechnical characterstics and able 
to float within 3 minutes. Formulation like F4, F8 and F9 
show higher floation capabilities as well as more steady 
state drug release profile. On comparative kinetic 
modeling study (such as Zero order, Higuchi model and 
Korsmeyer-Peppas model) it was found that all the 
formulation follow Higuchi model and correlation (R2) 
values were near to unity. Among those formulation F8 
and F9 showed R2 value of Higuchi model more near as 
compared to the other formulation. In kormeyer pepas 
model kinetic study it was found that all formulations 
follow non- fickian diffusion. 
The research entitled and result obtained reveals that the 
combine effect of floating agent in different ratio was 
suitable for long floating duration. 
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